About Zentalis

We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Using our industry expertise, we have developed an integrated approach to identify and overcome the limitations of current cancer therapeutics, enabling us to design better small molecules for improved patient outcomes.

Learn More

Pipeline

Drug NameDrug
DiseaseDis
IND EnablingIND
Phase 1/2Ph 1/2
Phase 3Ph 3
CollaboratorCollab
ZN-c5: Oral SERD
Monotherapy
ZN-c5: Oral SERD
Breast Cancer
Monotherapy
Zentera
ZN-c5: Oral SERD
Combinations
ZN-c5: Oral SERD
Breast Cancer
Combinations
Pfizer Lilly
ZN-c3: WEE1
Solid Tumors
ZN-c3: WEE1
Monotherapy
ZN-c3: WEE1
ZN-c3: WEE1
Solid Tumors
Monotherapy
Zentera
ZN-c3: WEE1
Combinations
ZN-c3: WEE1
Solid Tumors
Combinations
ZN-d5: BCL-2
AML or B-cell Lymphoma
ZN-d5: BCL-2
Monotherapy
ZN-d5: BCL-2
ZN-d5: BCL-2
AML or B-cell Lymphoma
Monotherapy
Zentera
ZN-d5: BCL-2
Breast Cancer
ZN-d5: BCL-2
Combination with ZN-c5
ZN-d5: BCL-2
ZN-d5: BCL-2
Breast Cancer
Combination with ZN-c5
ZN-e4: EGFR
NSCLC
ZN-e4: EGFR
ZN-e4: EGFR
ZN-e4: EGFR
NSCLC
SciClone

Learn More

Join Zentalis

Learn More